Document is current
Any future updates will be listed below
-
Authors
Jones, Veronica
Yin, Hongwei Holly
Yuan, Yate-Ching
Wang, Yongzhe
Li, Sierra Min
Aljaber, Dana
Sanchez, Angelica
Quinones, Christine
Schmolze, Dan
Yuan, Yuan
Mortimer, Joanne
Yee, Lisa
Kruper, Laura
Jovanovic-Talisman, Tijana
Tomsic, Jerneja
Sanchez, Nancy
Chavez, Tanya
O’Regan, Ruth M.
Khan, Qamar J.
Davis, Melissa
Kalinsky, Kevin
Meisel, Jane
Kittles, Rick
Rodriguez-Rodriguez, Lorna
Seewaldt, Victoria
-
Funding
Funding for this research was provided by:
K12 Paul Calabresi Career Development Award for Clinical Oncology
City of Hope (COH) Shared Resources Pilot Award
American Cancer Society-Institutional Research Grant
- License Information
-
More Information
Article History
Received: 31 October 2023
Accepted: 4 February 2025
First Online: 28 February 2025
Declarations
:
: Yuan Yuan declares Grant/Research Support from Imugene, Genentech, Pfizer, Merck, Edenbridge, Agenus; Consultant for Gilead Sciences and Novartis; On the Speakers Bureau for AstraZeneca, Daiichi-Sankyo, Merck, Pfizer and Gilead Sciences. Kevin Kalinsky declares Employment/Stock: Spouse—EQRX, Grail (Prior Employee); Advisory/Consulting: Eli-Lilly, Pfizer, Novartis, AstraZeneca, Daiichi Sankyo, Puma, 4D Pharma, Oncosec, Immunomedics, Puma, Merck, Seattle Genetics, Mersana, and Cyclocel; Institutional Research Funding: Genentech/Roche, Novartis, Eli-Lilly, AstraZeneca, Daiichi Sankyo, Ascentage. The remaining authors have no conflicts of interest.
